Abbvie Inc

NYSE:ABBV   3:59:59 PM EDT
118.53
+0.57 (+0.48%)
Products, Regulatory

Abbvie Provides Update Regarding Rinvoq® (Upadacitinib) In Psoriatic Arthritis And Ankylosing Spondylitis In The U.S.

Published: 06/25/2021 12:39 GMT
Abbvie Inc (ABBV) - Abbvie Provides Update Regarding Rinvoq® (upadacitinib) in Psoriatic Arthritis and Ankylosing Spondylitis in the U.S.abbvie - FDA Cited Its Ongoing Review of Pfizer's Post-marketing Study, Oral Surveillance, Evaluating Tofacitinib in Patients With Rheumatoid Arthritis.
Abbvie Inc - FDA Will Not Meet Prescription Drug User Fee Act (pdufa) Action Dates for Supplemental New Drug Applications (sndas) for Rinvoq.
Abbvie Inc - No Formal Regulatory Action Has Been Taken on Sndas for Rinvoq in Psoriatic Arthritis and Ankylosing Spondylitis.